Browsing by Author "Noshi, S.H"

Now showing 1 - 2 of 2

Concurrent tissue engineering and infection prophylaxis utilising stable dual action amoxicillin loaded scaffolds
(Editions de Sante, 2020-08) Elsayyad, N.M.E.; Salama, A; Noshi, S.H
View references (46) Scaffolds have proven to be beneficial biocompatible wound healing enhancers, however they don't guard against wound infections. The aim of this study is to formulate scaffolds loaded with Amoxicillin (AMX), a broad spectrum antibiotic to have a dual action of acceleration of wound healing as well as prevention of infection of the wound while simultaneously preserving AMX stability. A 24 full factorial design was applied to study the effect of the type of protein polymer (collagen/gelatin), type of crosslinker (chitosan/alginate), ratio of polymer to cross linker (70:30, 60:40) and the total percentage of polymers (4%, 16%) on the porosity, hardness and in vitro AMX release of the prepared scaffolds. The extent of cross linking between polymers used was also simulated using Maestro® software. The morphology, compatibility, release and stability of the optimized formula was studied on vitro as well as in vivo activity by determining the wound healing rate as well as histopathological and biochemical analysis of MMP9 and TNF- α in rats. Optimized AMX loaded scaffolds formed of collagen/chitosan was found to have superior properties with porous structure, 8.62 ± 0.32 Kp hardness, 0.984 ± 0.068 porosity, 98.65 ± 7.62% drug content as well as sustained release of AMX over 24 h. The optimized formula has shown good stability properties in accelerated conditions over 6 months. Histopathological studies confirmed the enhanced wound healing properties of the optimized AMX loaded scaffolds as well as significantly reduced inflammation markers (MMP9 and TNF- α) in rats compared to the untreated groups. Thus it can be concluded that AMX loaded scaffolds are a promising wound healing means with various applications owing to their tissue engineering and infection from prophylaxis as well as increased stability. © 2020 Elsevier
Soluplus® based solid dispersion as fast disintegrating tablets: a combined experimental approach for enhancing the dissolution and antiulcer efficacy of famotidine
(Taylor and Francis Ltd., 1/23/2020) Basha, M.; Salama, A; Noshi, S.H
Famotidine (FM) is considered among the first-line therapy for treatment of gastric ulcers; however, its poor aqueous solubility resulted in low bioavailability and limited therapeutic efficacy. Therefore, fast disintegrating tablet (FDT) incorporating FM solid dispersion was developed in a combined formulation approach for efficient treatment of ulcers. Within the investigated polymers, solid dispersions were prepared using the novel copolymer, Soluplus® (SP) by kneading and freeze-drying techniques at various FM:SP ratios. FM solid dispersion prepared at 1:10 ratio using freeze drying (FM-SP10) manifested the highest saturation solubility, having smooth porous surface with the complete conversion of FM to the amorphous form. FDTs of FM-SP10 was produced by direct compression using three ready-to-use excipients; F-melt, Pearlitol Flash, and Fujicalin. All tablets showed adequate thickness, diameter, weight variation, drug content, and friability (<1%). Fujicalin-FDTs (FM-FDT-FU) exhibited the shortest disintegration time with almost complete dissolution of the drug (>95%) within 30 min. It also revealed remarkable antiulcerogenic effect on ethanol induced gastric ulcers in terms of ulcer and protection indices compared to the market product. Pretreated rats with FM-FDT-FU demonstrated normal gastric area with the absence of edema and leucocytes infiltration, supported by the histological examination. FM-FDT-FU administration protected the stomach from oxidative damage and severe inflammatory response via the significant increase of glutathione level and the decreased levels of nitric oxide, interleukin and cyclooxygenase. Thus, the present study provides a promising dosage form of FM characterized by superior antiulcerogenic potential with desired tableting properties. © 2020, © 2020 Informa UK Limited, trading as Taylor & Francis Group.